New Delhi: Optimus Pharma on Thursday (December 30, 2021) launched Molnupiravir Anti-Covid Pill, for limited use in emergency situations, in Hyderabad.
Molnupiravir is an antivirus that inhibits SARS-COV-2 replication by the mutagenesis virus. The tablet is authorized for anyone aged 18 or more. After someone was tested positive for Covid-19, he had to take two 800 mg tablets for 5 days to complete treatment. It can be noted that the cost of each anti-covid pill Molnupiravir is Rs 63.
Previously, while expanding the Indian basket of the Covid-19 vaccine, the country’s drug regulator, Indian drug controller drug (DCGI), gave a very-awaited anti-covid pill molnupiravir for limited emergency use.
Meanwhile, the company, in a press release, said successfully completing clinical trial phase 3 in 1,218 subjects in 29 geographical study sites throughout India.
“We want to discuss the maximum demographic diversity into our trial to get data in various geographical regions of the country and conclusive evidence that Molnupiravir is able to bring a reduction in viral load for 5 days of treatment duration,” Chairman and Managing Director of Optimus Pharma, D Srinivasa Reddy said.
Optimus Pharma has revealed drug yields that are very promising in their ability to reduce viral load and issue significant symptomatic improvements in the patient’s health.
Meanwhile, Sun Pharma, at the beginning of the day, said his subsidiary had received authorization of emergency use (EUA) from the drug controller General India (DCGI) to produce and market the generic version of MSD and Ridgeback Molnupiravir antivirus drugs under the name of the Molxvir brand in India.
“Antivirus drugs will now be produced in this country by 13 companies for limited use under the emergency situation for the treatment of adult patients with Covid-19 and who have a high risk of disease development,” said Minister of Health Mandaviya.
UK Mhra on December 4 gave approval for molnupiravir with special conditions for the treatment of mild to moderate Koronavirus disease in adults with a positive SARS-COV-2 diagnostic test and which has at least one risk factor to develop severe illness, the statement said.
The US FDA on December 23 has provided EUA to Molnupiravir for the treatment of mild to moderate coronavirus disease (Covid-19) in adults with positive results from direct STARS-COV-2 viral testing, and at high risk for development. For severe Covid-19, including hospitalization or death, and for whom the option of Covid-19-19 alternative treatment authorized by the FDA cannot be accessed or clinically appropriate.
